A number of other equities analysts also recently commented on the stock. Canaccord Genuity restated a buy rating and set a GBX 84 ($1.10) price objective on shares of Vernalis plc in a research note on Friday, July 8th. Panmure Gordon restated a buy rating and set a GBX 76 ($0.99) price objective on shares of Vernalis plc in a research note on Thursday, September 22nd. Shore Capital restated a house stock rating on shares of Vernalis plc in a research note on Tuesday, July 19th. Finally, N+1 Singer restated a hold rating and set a GBX 46 ($0.60) price objective on shares of Vernalis plc in a research note on Thursday, September 29th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of GBX 73 ($0.95).
Shares of Vernalis plc (LON:VER) opened at 41.00 on Thursday. Vernalis plc has a 12-month low of GBX 31.00 and a 12-month high of GBX 79.00. The firm’s 50-day moving average price is GBX 43.46 and its 200-day moving average price is GBX 45.40. The firm’s market capitalization is GBX 215.74 million.
In other news, insider Carol Ferguson bought 28,000 shares of the company’s stock in a transaction dated Friday, September 30th. The shares were bought at an average cost of GBX 41 ($0.54) per share, with a total value of £11,480 ($14,984.99).
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.